Worth reading
42Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Conditional
How definitive the wording is.Announced details
KOBGOZE® intramuscular injection
Applicable field (uses covered by this announcement)
Prevention of COVID-19, booster immunization
Impact on Business Performance
The impact on consolidated results for the fiscal year ending March 2027 has already been incorporated into the earnings forecast
The company does not address Contract Value / Offering price.
| Item | Details |
|---|---|
| Names of Products / Services Covered | KOBGOZE® intramuscular injection |
| Applicable area | Prevention of COVID-19, booster immunization |
| Impact on Business Performance | The impact on consolidated results for the fiscal year ending March 2027 has already been incorporated into the earnings forecast |
Items this document does not state (15)
CounterpartyCounterparty overviewRelationship with the CompanyContract ValueOffering priceContract DateLaunch dateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage historySource
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To address the continuously evolving SARS-CoV-2 virus, the company is building a vaccine platform that can rapidly respond to the strains recommended for each season, based on approvals obtained for the original strain and the JN.1 strain. The company states that this approval has established the foundation for the platform.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.